Company Insights

PAVM customer relationships

Explore interactive graphBrowse insights index
PAVM customer relationship map

PAVmed’s customer map: how EsoGuard, Lucid and a growing set of partners drive commercial value

PAVmed (PAVM) generates revenue through a hybrid model that combines laboratory testing services (EsoGuard), recurring management fees from its Lucid Diagnostics subsidiary, and strategic commercial partnerships. The company monetizes by operating a CLIA-certified lab that sells EsoGuard esophageal DNA tests to providers and patients, while capturing steady income via a management services agreement (MSA) and by leveraging institutional partnerships that can scale test volumes and reimbursement access.

If you want a consolidated view of PAVmed’s commercial relationships and implications for revenue and risk, visit the company hub at https://nullexposure.com/.

How investors should read the relationship signals

PAVmed’s commercial posture blends short-duration transactional testing with at least one explicit long-term service relationship. The company treats individual test orders as short-term performance obligations—tests are processed and settled well under one year—while the MSA that drives management fee income is structured as a longer-term, cancellable arrangement with periodic fee adjustments. Geographically, revenue is concentrated in the United States, and counterparty types include both individual patients (the ultimate payor for many tests) and government buyers when contracts are awarded. Collectively, these signals point to a commercial-stage business where lab services are core, services and software complement scale, and reimbursement policy is a material risk.

Detailed relationship entries (each source in the record)

Ohio State — earnings call (2025Q3)

PAVmed reported that Ohio State has a call center integration and the company has learned to interface with it so alerts from PAVmed’s platform are processed efficiently, indicating operational connectivity with a major health system. This was disclosed on PAVmed’s 2025Q3 earnings call (transcript filed Mar 7, 2026).

Lucid Diagnostics Inc. — TradingView SEC-10Q summary (FY2025)

A TradingView summary of PAVmed’s SEC 10‑Q explains that Lucid’s daily operations are supported by personnel under a management services agreement that generates management fee income for PAVmed. The note references Lucid’s management-fee relationship (TradingView, March 2026).

U.S. Department of Veterans Affairs — MEXC press recap (FY2026)

PAVmed’s press release announced that the VA has partnered with Lucid to expand access to the EsoGuard Esophageal DNA Test across the VA healthcare system, signaling a government procurement that broadens distribution to a network serving millions of veterans (MEXC, January 2026 press recap).

Lucid Diagnostics / VA contract — SahmCapital press release (FY2026)

Lucid Diagnostics, described as a commercial-stage diagnostic subsidiary of PAVmed, was awarded a VA contract for EsoGuard, explicitly expanding access across the VA system and positioning Lucid to serve an integrated healthcare buyer with over nine million enrolled veterans (SahmCapital, January 21, 2026).

VA contract coverage — Invezz market commentary (FY2026)

Market commentary at Invezz recapped PAVmed’s press release and framed the VA engagement as a distribution and commercialization milestone for EsoGuard, helping explain the surge in investor interest after the award (Invezz, January 21, 2026).

VA contract market reaction — StockTwits news article (FY2026)

StockTwits reported shares of PAVmed jumped more than 250% after Lucid won the VA contract to supply EsoGuard, underscoring the market’s view of the contract as earnings-accretive or materially derisking commercial scale (StockTwits, January 2026).

OSU commercial partnership — earnings call (2025Q3)

PAVmed stated on its 2025Q3 earnings call that it launched the commercial phase of a strategic partnership with OSU, indicating a move from pilot to commercial activity with a large academic health system (PAVmed 2025Q3 earnings call, Mar 7, 2026).

VA contract summary in broader feeds — Intellectia news aggregator (FY2026)

An Intellectia headline reiterated that a PAVmed subsidiary secured a VA contract to expand EsoGuard access across the VA’s network of more than nine million veterans, reinforcing the same commercial fact disseminated across multiple outlets (Intellectia, January 2026).

What this relationship mix means for revenue, risk and strategy

  • Revenue drivers: The core revenue engine is EsoGuard laboratory testing, supported by MSA fee income from Lucid. The VA contract represents a potentially large volume channel that can materially increase test throughput and stabilize revenue mix.
  • Contracting posture: The company runs two contract tempos in parallel — short-cycle test orders (turnaround and recognition in under a year) and a long-term, adjustable MSA with Lucid that provides recurring monthly fee income. The MSA is a structurally important long-term contract for fee stability.
  • Concentration and geography: Business is US-centric with revenue historically concentrated domestically; larger institutional buyers like the VA could change payer mix but will raise scrutiny on reimbursement and compliance.
  • Counterparty criticality: Relationships with government payors and major health systems are high-impact: a VA contract increases scale but also ties performance to government procurement and payment practices.
  • Business maturity: PAVmed sits at commercial-stage lab operations with ongoing rollouts (OSU partnership, VA contract) that transition prior R&D upside into revenue execution. The firm remains sensitive to reimbursement policy, which is a material business risk.
  • Segment mix: Primary revenue is core product (EsoGuard) and services (lab testing/MSA); software (Veris platform) is a complementary, recurring-revenue signal but not the current top-line driver.

Key takeaways for investors

  • Lucid’s MSA is a strategic revenue anchor. The company already documents recurring monthly fees and fee increases, establishing a baseline of management income that reduces pure test-volume cyclicality.
  • The VA contract is a high-leverage commercial moment. If Lucid executes, EsoGuard gains scale and a potentially diversified payer mix; market reaction already reflects that perceived value.
  • Reimbursement remains the single largest material risk. PAVmed’s test economics and expansion depend on payer coverage and rates; government and MAC (MolDx/Palmetto) interactions are decisive.
  • Operational execution matters. Integration with large health systems (OSU, Ohio State call center) demonstrates the company can operationalize logistics, an often-overlooked gating factor for diagnostic scale.

For a concise, investor-focused summary and more relationship mapping, go to https://nullexposure.com/.

Recommended investor actions

  • Review Lucid’s MSA terms and disclosures to quantify recurring fee visibility and termination provisions.
  • Monitor VA contract implementation and billing cadence to assess realized test volumes and reimbursement outcomes.
  • Track reimbursement updates from CMS/MolDx and state Medicare contractors that determine EsoGuard’s revenue per test.
  • Evaluate partnerships (OSU, Ohio State) for evidence of sustainable referral flows versus one-off pilots.

Explore PAVmed’s customer and partner intelligence at https://nullexposure.com/ for ongoing updates and curated signals.

By mapping each public relationship and aligning them with contract and commercial signals, investors get a clearer view of how PAVmed converts clinical assets into recurring revenue — and where execution and reimbursement will decide valuation outcomes.